A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Conditions

• Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• TORL-5-700 — DRUG
  Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
• TORL-5-700 at MTD/RP2D — DRUG
  Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
• TORL-5-700 at MTD/RP2D in combination with another agent — DRUG
  Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Study Details

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Key Dates

First listed

Feb 27, 2026

Start date

Mar 31, 2026

Status verified

Jun 2026

Primary completion

Mar 31, 2029

Completion

Sep 30, 2029

Study Design

Enrollment

155 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Part 1: Monotherapy Dose Escalation
  TORL-5-700 Administered once every three weeks
• Experimental: Part 2: Monotherapy Expansion
  TORL-5-700 at MTD/RP2D Administered once every three weeks
• Experimental: Part 3: Combination Evaluation
  TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Primary Outcome Measure

Evaluate the safety of TORL-5-700 as a monotherapy [ Time Frame: though study completion, an average of 2.5 years ]

Central Contacts

• Timothy Welliver, M.D.
  (310) 598-5969
  [email protected]

Locations (3)

Find similar trials in Santa Monica, CA